Introduction {#s1}
============

Unhealthy diet and physical inactivity are the major culprits to the obesity crisis, although other environmental factors may also contribute ([@B1]). An overlooked component in energy balance is adaptive thermogenesis, which comprises diet-induced thermogenesis (DIT) and cold-induced thermogenesis (CIT). DIT is the portion of energy expended after food ingestion, beyond the energy cost of digestion/absorption ([@B2]). The CIT response defends core temperature during cold exposure ([@B3]). In rodents, both processes are chiefly regulated by brown adipose tissue (BAT). Through the action of uncoupling protein 1 (UCP1), energy is converted into heat and represents a form of energy expenditure (EE) as energy is dissipated to the environment. BAT stimulation protects animals against diet-induced obesity and glucose intolerance ([@B4]).

In addition to "classic BAT" in the interscapuar region, cold exposure also induces the emergence of brown adipocyte-like cells (beige/brite adipocytes) within white adipose tissue (WAT) in animals ([@B5],[@B6]). Brown/beige fat generates heat from glucose/lipids, and their high substrate utilization underlies protection against diet-induced insulin resistance in genetic, pharmacological, and/or transplantation models of invigorated brown/beige fat status ([@B7]--[@B9]). In humans, histological examination had demonstrated the presence of BAT in adult in the 1970--1980s ([@B10]--[@B12]), although BAT whole-body abundance was not fully appreciated until its visualization was made possible by positron emission tomography (PET)/computed tomography (CT) ([@B13]--[@B17]). BAT is not only inducible in humans ([@B18],[@B19]) but also exhibits oxidative capacity ([@B20]) and classic BAT/beige fat features ([@B21],[@B22]), thus forming the basis for the quest of BAT/beige fat-enhancing strategies as antiobesity treatments ([@B23]).

Acute cold exposure (hours) increases BAT activity ([@B13],[@B15]--[@B17],[@B24]), while longer-term exposure (days/weeks) expands BAT volume ([@B25],[@B26]). Because BAT recruitment could reduce adiposity ([@B26]), it suggests that BAT may impact whole-body energy homeostasis. The corollary is that reduced cold exposure could suppress BAT/beige fat function in humans, with potential obesogenic consequences ([@B27]). To date, cold exposure is the best-known activator ([@B15]--[@B17]) and recruiter ([@B25],[@B26]) of BAT, and associative data have linked higher BAT abundance with leanness and lower glycemia in humans ([@B13],[@B15],[@B28],[@B29]). Whether BAT withers under warm exposure and whether BAT recruitment triggers compensatory metabolic and/or behavioral adaptations have not been investigated but are integral to BAT physiology. Rodent studies have revealed a complex interplay between housing temperature, BAT recruitment, and energy balance, which ultimately determines metabolic phenotype ([@B30]). For better appreciation of the metabolic significance of human BAT and the implications of BAT status on health, BAT recruitment interventions should be examined in the context of whole-body energy metabolism.

In this study, we investigated the effects of long-term mild cold and warm exposure by minimal overnight manipulation of ambient temperature on individual BAT status and the corresponding energy/substrate homeostatic responses. We hypothesized that human BAT exhibits plasticity and its activity modulates systemic energy metabolism.

Research Design and Methods {#s2}
===========================

Subjects {#s3}
--------

Five healthy men were recruited through local advertisement and provided written informed consent. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)--National Institute of Arthritis and Musculoskeletal and Skin Diseases Institutional Review Board approved the study: Impact of Chronic Cold Exposure in Humans (ICEMAN). [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1) summarizes recruitment, allocation, and intervention.

Overall Design {#s4}
--------------

This is a prospective crossover study consisting of four consecutive blocks of 1-month duration ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)): it incorporates *1*) sequential monthly thermal acclimation over 4 months and *2*) acute thermometabolic evaluations at the end of each study temperature regimen. Volunteers were admitted to the Clinical Research Unit (NIDDK) in Bethesda, MD, (April--November 2013) for the entire 4 months.

Monthly Thermal Acclimation {#s5}
---------------------------

Volunteers resided in a temperature-adjusted private room, engaged in usual daily activities, and returned to their room each evening. Room temperature was adjusted in the following sequence: 24°C (month 1) → 19°C (month 2) → 24°C (month 3) → 27°C (month 4). Volunteers were exposed to the study temperature for at least 10 h each night, wearing standardized hospital clothing with a combined thermal insulation value of 0.4 (clo). Only bedsheets were provided. Volunteers were asked to not deviate daily activity level over the study period. Each subject therefore acted as his own control. At 0800 h at the end of each month, volunteers were admitted to a whole-room indirect calorimeter for thermometabolic evaluation.

Temperature Monitoring {#s6}
----------------------

Volunteers wore two temperature data loggers (cat. no. RHT20; Extech, Nashua, NH): one "external to clothing" to track environmental temperature and the other "within clothing" to track immediate temperature changes in the "microenvironment" within clothing. We averaged individual exposed temperature every 30 min for the entire 4-month period, allowing us to record environmental temperature variations and the "true temperatures" the individual was being exposed to.

Diet {#s7}
----

All meals, including prepacked lunches/snacks, were provided with the following composition: 50% carbohydrate, 20% protein, and 30% fat. The first month was an equilibration period, during which volunteers followed a weight-maintenance diet. After month 1, subjects ate according to hunger. Caloric/macronutrient content was calculated based on weight-maintenance requirements, determined during equilibration month. Any unconsumed foods were returned/weighed for energy/macronutrient intake calculation. Subjects met study dietitians twice weekly to verify food diaries/compliance. Total intake/macronutrient was computed/analyzed using three-dimensional food models (ProNutra, version 3.4.0.0.; Viocare Technologies, Princeton, NJ).

Appetite/Hunger Assessment {#s8}
--------------------------

Subjects completed questionnaires assessing appetite twice a week before/after breakfast by marking on a visual analog scale (VAS) (10 cm long) responses to the following questions: *1*) How hungry are you? *2*) How full are you? *3*) How much food can you consume? These questions gauged hunger, satiety, and desire to eat before/after meals.

Before each monthly thermaometabolic evaluation, volunteers underwent an ad libitum meal test, consisting of a selection of food items displayed in a vending machine. Subjects ate until they felt "comfortably full." Total energy/macronutrient intake were recorded, together with ratings of appetite (hunger, satiety, and desire to eat) using the same weekly questionnaire at *T* = −10, 0, 60, 120, 180, 240, and 300 min where initiation of the meal was defined as *T* = 0 min.

Acute Thermometabolic Evaluations {#s9}
---------------------------------

Thermometabolic evaluation was scheduled at the end of each month ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)), modeled on our previous published methods ([@B24],[@B31]), with total EE calculated as previously described ([@B24],[@B31]). Volunteers underwent two 24-h sessions in a whole-room calorimeter, exposed to first 24°C (day 1) and then 19°C (day 3), with a resting 24-h period in between. The temperature order was not randomized because our previous study did not reveal a sequence effect ([@B31]). Testing at the two temperatures allowed us to evaluate how monthly acclimation modulated EE/metabolism at both thermoneutral and mild cold conditions. Lunch (Boost Plus; Nestlé Healthcare Nutrition, Inc., Vevey, Switzerland) and dinner (selected from Metabolic Menu) were provided at 1300 and 1900 h, consisting of one-third and two-thirds of daily caloric intake, respectively, based on calculation from equilibration month. CIT was calculated as difference in total EE between 24°C and 19°C and DIT as difference in pre- (0800--1300 h) and post- (1300--1900 h) lunch EE. As the test meal carried identical caloric and macronutrient content, we attributed any changes observed to arise from adaptive thermogenesis because the facultative component (i.e., digestion/absorption) should be relatively unaltered. Shivering response was quantified by surface electromyography (EMG), as previously described ([@B32]), and volunteers reported perception to cold each month during EE testing using VAS. Hormonal/metabolic parameters were measured in venous samples. Postprandial insulin sensitivity was calculated after a mixed meal ([@B33]) and adipose resistance index as the product of free fatty acid × insulin. At the conclusion of the thermometabolic study, body composition was measured, as previously published ([@B24],[@B31]).

PET/CT Scanning {#s10}
---------------

PET/CT was performed using Siemens Biograph mCT (Siemens Healthcare) ([@B32]). PET/CT was undertaken at 0800 h the morning after the 19°C testing day at the end of each acclimation month. Attenuation-corrected PET/CT images were analyzed using custom software built with IDL (Exelis Visual Information Solutions, Inc., Boulder, CO). A three-dimensional region of interest (ROI) was defined cranially by a horizontal line parallel to the base of the C4 vertebra and caudally by an oblique line traversing the manubriosternal joint and T8 transverse process ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)). BAT was defined as tissue with Hounsfield units (HU) −300 to −10 on CT (i.e., fat density) with a lean body mass standardized uptake value (SUV) of ≥2 (i.e., high glucose uptake). The chosen ROI captures major BAT depots in the cervical, supraclavicular, axillary, superior mediastinal, and paravertebral areas. This ROI was chosen because spurious myocardial/renal excretory fluorodeoxyglucose (FDG) uptake could not be reliably excluded from BAT. This approach allowed examination of BAT evolution within a well-defined region of adipose tissue across 4 months.

PET/CT Parameters {#s11}
-----------------

The following parameters were analyzed: BAT volume, mean SUV, and activity. BAT volume, defined as the sum of the volume of all voxels that met HU-SUV criteria, represents activated BAT. Mean SUV (normalized by FDG dose and lean body mass) of ROI represents mean metabolic activity within BAT-harboring region. BAT activity represents the total radioactivity (in MBq) within ROI and captures both changes in volume and mean FDG uptake. Furthermore, because fat exhibits metabolic activity as a continuum and the chosen SUV threshold of ≥2 is arbitrary and may potentially exclude more diffuse enhancement of adipose metabolic activity, we also quantified mean SUV in the entire ROI within tissue of fat density (HU: −300 to −10). Mean SUV of whole fat depot estimates overall metabolic activity and may capture both BAT and diffuse beige fat activity. This is particularly relevant in subjects with lower BAT abundance ([Supplementary Figs. 5 and 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)). While BAT, defined with an SUV threshold of ≥2, was not visually apparent in these two subjects, whole fat activity followed the same pattern of acclimated BAT changes. When a lower SUV was used (≥1) ([Supplementary Fig. 8](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)), adipose activity changes were visually concordant with overall fat activity. Mean SUV uptake in liver and skeletal muscle (rectus femoris) was quantified to compare temperature-acclimation impact on BAT and other metabolic organs. All images were analyzed twice by an investigator (P.L.) blinded to subject identity and acclimation temperature. Intrascan coefficient of variation of BAT volume, mean SUV, BAT activity, and mean whole fat activity were 0.7%, 3.0%, 1.3%, and 2.4%, respectively.

Tissue Biopsies {#s12}
---------------

Paired subcutaneous adipose/muscle biopsies were obtained at the end of each month from abdomen and rectus femoris, respectively ([@B31]). RNA extraction and cDNA synthesis were performed using standard methods, and genes governing thermogenesis and glucose metabolism were examined using TaqMan Gene Expression assays (Applied Biosystems) ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)).

Laboratory Measurements {#s13}
-----------------------

Plasma adiponectin, leptin, and fibroblast growth factor 21 (FGF21) were measured by ELISA (R&D Systems, Minneapolis, MN, and BioVendor, Oxford, U.K.), according to manufacturer's protocol, with intra-assay/interassay coefficients of variation between 2.5 and 4.8%. Remaining tests were measured by the Department of Laboratory Medicine, National Institutes of Health (NIH).

Statistical Analysis {#s14}
--------------------

Statistical analysis was performed using SPSS 20.0 (SPSS, Inc., Chicago, IL). Data are expressed as means ± SD. Trend changes of physiologic and hormonal parameters during temperature acclimation across 4 months, expressed as fold change over baseline, were analyzed by one-way ANOVA with Bonferroni correction. Areas under the curve (AUCs) were calculated using the trapezoidal rules incorporating sampling points across a 24-h period from 0800 to 0700 h the next morning ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)). Postprandial glucose and insulin AUCs were calculated in the period after lunch starting at 1300 h (*T* = 0, 60, 120, 240, and 360 min). Pearson correlation coefficients were used to examine associations between variables. An α-error of 0.05 was considered statistically significant.

Results {#s15}
=======

Baseline Acute Thermometabolic Evaluation {#s16}
-----------------------------------------

Five men (21 ± 2 years old, BMI 22 ± 1 kg/m^2^, body fat 21 ± 2%) participated in the study. Volunteers were first evaluated at baseline for BAT status and thermometabolic responses to temperature changes. Compared with 24°C, mild cold exposure at 19°C increased total EE by 6 ± 4% (*P* \< 0.05), representing CIT response. Baseline cold-activated BAT volume was 55 ± 61 mL, with a mean SUV of 3.2 ± 0.8. EE at 19°C correlated positively with BAT volume (*R*^2^ = 0.82, *P* = 0.03). These results replicated findings in our previous overnight cold exposure studies ([@B24],[@B31]) and validated the methodology in the investigation of temperature acclimation--associated metabolic and physiologic consequences. Hereafter, we describe changes in physiologic and metabolic parameters at each monthly thermometabolic evaluation, with results stratified to either the 19°C or the 24°C testing condition to decipher impact of acclimation on metabolism under thermoneutrality and mild cold exposure.

Metabolic Consequences of Monthly Acclimation {#s17}
---------------------------------------------

[Tables 1](#T1){ref-type="table"}--[4](#T4){ref-type="table"} summarize changes in BAT and physiologic, dietary, body compositional, and hormonal parameters across the 4-month acclimation. Hormone/metabolite AUC results are shown in [Table 4](#T4){ref-type="table"} and fasting levels in [Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1). Results from each domain are described in the following subsections.

###### 

PET/CT parameters across 4 months of acclimation

                          Month 1: 24°C   Month 2: 19°C                                  Month 3: 24°C   Month 4: 27°C   *P*~trend~
  ----------------------- --------------- ---------------------------------------------- --------------- --------------- ------------
  BAT volume (mL)         55 ± 61         78 ± 84[^a^](#t1n1){ref-type="table-fn"}       63 ± 81         58 ± 81         0.036
  BAT mean SUV            3.2 ± 0.8       3.8 ± 1.3                                      3.4 ± 1.0       3.4 ± 0.8       0.35
  BAT activity (MBq)      0.65 ± 0.76     1.0 ± 1.3[^a^](#t1n1){ref-type="table-fn"}     0.8 ± 1.1       0.7 ± 1.0       0.038
  BAT radiodensity (HU)   −58.8 ± 7.2     −44.2 ± 6.8                                    −55.4 ± 6.5     −69.2 ± 6.8     \<0.01
  Whole fat mean SUV      0.61 ± 0.13     0.68 ± 0.18[^a^](#t1n1){ref-type="table-fn"}   0.63 ± 0.17     0.59 ± 0.16     0.035
  Muscle mean SUV         0.46 ± 0.08     0.41 ± 0.04                                    0.43 ± 0.05     0.48 ± 0.08     0.52
  Liver mean SUV          1.68 ± 0.08     1.50 ± 0.14                                    1.61 ± 0.15     1.67 ± 0.16     0.15

Data are means ± SD. At the end of each testing month, subjects underwent acute thermometabolic evaluation at either 24°C or 19°C.

^a^*P* \< 0.05 (month 1 vs. 2).

###### 

Physiologic parameters across 4 months of acclimation

                                           Month 1: 24°C   Month 2: 19°C                                  Month 3: 24°C   Month 4: 27°C                                                                      *P*~trend~                                                                                                                       
  ---------------------------------------- --------------- ---------------------------------------------- --------------- ---------------------------------------------------------------------------------- ------------- ---------------------------------------------- ------------- ---------------------------------------------- ------ ------
  Total EE (kcal)                          2,472 ± 180     2,624 ± 198[^a^](#t2n1){ref-type="table-fn"}   2,366 ± 358     2,543 ± 410[^a^](#t2n1){ref-type="table-fn"}                                       2,400 ± 252   2,555 ± 346[^a^](#t2n1){ref-type="table-fn"}   2,341 ± 255   2,505 ± 322[^a^](#t2n1){ref-type="table-fn"}   0.45   0.46
  Respiratory quotient                     0.84 ± 0.03     0.84 ± 0.01                                    0.84 ± 0.02     0.83 ± 0.02                                                                        0.85 ± 0.02   0.84 ± 0.02                                    0.84 ± 0.03   0.85 ± 0.02                                    0.72   0.47
  Total activity (units)                   8.4 ± 1.6       8.4 ± 2.8                                      7.6 ± 2.9       7.1 ± 2.4                                                                          6.8 ± 3.7     7.1 ± 4.1                                      7.9 ± 5.0     7.2 ± 4.7                                      0.54   0.38
  Surface electromyography (×10^−6^ RMS)   2.8 ± 0.4       2.5 ± 1.3                                      2.7 ± 0.3       2.6 ± 0.2                                                                          2.8 ± 0.5     2.7 ± 0.2                                      2.8 ± 0.3     2.6 ± 0.4                                      0.98   0.83
  CIT (%)                                  6.2 ± 4.1       7.4 ± 3.1                                      6.2 ± 3.9       6.8 ± 3.2                                                                          0.16                                                                                                                             
  DIT (%)                                  10.3 ± 13.1     33.4 ± 18.2                                    19.0 ± 15.4     42.2 ± 17.4[^a^](#t2n1){ref-type="table-fn"}^,^[^b^](#t2n2){ref-type="table-fn"}   19.1 ± 16.0   37.1 ± 19.6^a^                                 22.5 ± 11.0   34.4 ± 19.2[^a^](#t2n1){ref-type="table-fn"}   0.30   0.36

Data are means ± SD. At the end of each testing month, subjects underwent acute thermometabolic evaluation at either 24°C or 19°C. RMS, root mean square.

^a^*P* \< 0.05 compared with 24°C during acute thermometabolic evaluation each month;

^b^*P* \< 0.05 (month 1 vs. 2) compared with matching measurement at same temperature performed at respective months as indicated.

###### 

Nutritional and body compositional parameters across 4 months of acclimation

                          Month 1: 24°C   Month 2: 19°C                                                                     Month 3: 24°C   Month 4: 27°C   *P*~trend~
  ----------------------- --------------- --------------------------------------------------------------------------------- --------------- --------------- ------------
  Dietary intake                                                                                                                                            
   Caloric (kcal/day)     2,530 ± 321     2,620 ± 412                                                                       2,623 ± 342     2,514 ± 359     0.32
   Protein (g/day)        126 ± 16        131 ± 19                                                                          131 ± 15        127 ± 18        0.35
   Fat (g/day)            88 ± 9          91 ± 13                                                                           93 ± 11         86 ± 10         0.16
   Carbohydrate (g/day)   319 ± 42        331 ± 51                                                                          329 ± 44        320 ± 48        0.44
  Appetite/hunger VAS                                                                                                                                       
   Hunger AUC             13.1 ± 6.3      20.7 ± 7.0                                                                        17.5 ± 6.1      15.5 ± 3.5      0.13
   Satiety AUC            35.8 ± 4.6      25.7 ± 8.5                                                                        25.5 ± 5.4      27.9 ± 7.9      0.09
   Desire to eat AUC      14.6 ± 4.3      20.1 ± 3.4[^a^](#t3n1){ref-type="table-fn"}^,^[^b^](#t3n2){ref-type="table-fn"}   17.9 ± 4.2      16.5 ± 5.3      0.003
  Body composition                                                                                                                                          
   Body weight (kg)       74.4 ± 7.3      74.8 ± 7.5                                                                        74.9 ± 7.4      74.7 ± 7.7      0.72
   Lean mass (kg)         55.8 ± 6.0      56.3 ± 6.1                                                                        56.6 ± 6.3      56.1 ± 6.4      0.56
   Fat mass (kg)          14.6 ± 0.5      14.5 ± 0.8                                                                        14.6 ± 1.4      14.7 ± 1.7      0.95
   % body fat             20.92 ± 2.00    20.62 ± 1.64                                                                      20.64 ± 2.22    20.88 ± 2.51    0.99

Data are means ± SD. At the end of each testing month, subjects underwent acute thermometabolic evaluation at either 24°C or 19°C.

^a^*P* \< 0.05 (month 1 vs*.* 2),

^b^*P* \< 0.05 (months 2 vs. 4) compared with matching measurement at same temperature performed at respective months as indicated.

###### 

Hormonal and metabolic parameters across 4 months of acclimation

                                             Month 1: 24°C   Month 2: 19°C   Month 3: 24°C                                  Month 4: 27°C                                                                   *P*~trend~                                                                                                                   
  ------------------------------------------ --------------- --------------- ---------------------------------------------- ------------------------------------------------------------------------------- ------------- ------------- -------------------------------------------- ------------------------------------------ -------- --------
  Sympathoadrenal                                                                                                                                                                                                                                                                                                                        
   Urinary epinephrine (μg/day)              7.5 ± 5.0       8.0 ± 4.8       7.5 ± 3.9                                      8.3 ± 5.6                                                                       7.5 ± 4.4     7.7 ± 4.6     8.3 ± 6.1                                    7.7 ± 5.1                                  0.97     0.94
   Urinary norepinephrine (μg/day)           46 ± 29         53 ± 14         56 ± 30                                        64 ± 20                                                                         35 ± 9        61 ± 18^a^    37 ± 5                                       58 ± 24                                    0.42     0.56
  Glucocorticoid axis                                                                                                                                                                                                                                                                                                                    
   ACTH AUC (pg ⋅ min/mL)                    207 ± 61        199 ± 73        199 ± 51                                       197 ± 65                                                                        203 ± 74      176 ± 61      209 ± 71                                     199 ± 83                                   0.20     0.40
   Cortisol AUC (μg ⋅ min/mL)                0.96 ± 0.14     0.91 ± 0.13     0.87 ± 0.10                                    0.95 ± 0.12                                                                     0.81 ± 0.13   0.84 ± 0.17   0.90 ± 0.15                                  0.88 ± 0.22                                0.14     0.39
   Urinary cortisol (μg/day)                 49 ± 9          36 ± 13         49 ± 27                                        39 ± 9                                                                          39 ± 11       38 ± 11       39 ± 22                                      49 ± 21                                    0.42     0.25
  Thyroid axis                                                                                                                                                                                                                                                                                                                           
   TSH AUC (μIU ⋅ min/mL)                    7.8 ± 3.5       8.0 ± 2.8       7.5 ± 3.6                                      7.3 ± 2.1                                                                       8.6 ± 4.3     7.3 ± 2.2     8.8 ± 3.5[^c^](#t4n3){ref-type="table-fn"}   7.6 ± 1.9                                  0.38     0.39
   Free T4 AUC (pg ⋅ min/mL)                 95 ± 13         95 ± 9          93 ± 12                                        92 ± 12                                                                         93 ± 9        93 ± 11       90 ± 9                                       94 ± 9                                     0.39     0.54
   Free T3 AUC (pg ⋅ min/mL)                 26 ± 1          27 ± 1          29 ± 2[^b^](#t4n2){ref-type="table-fn"}        28 ± 1                                                                          28 ± 3        27 ± 2        26 ± 2[^d^](#t4n4){ref-type="table-fn"}      28 ± 2                                     0.16     0.59
   Free T3/free T4 AUC                       2,381 ± 490     2,410 ± 345     2,642 ± 574[^b^](#t4n2){ref-type="table-fn"}   2,556 ± 393                                                                     2,513 ± 449   2,511 ± 466   2,515 ± 481                                  2,491 ± 403                                0.06     0.41
  Glucose and lipid metabolism                                                                                                                                                                                                                                                                                                           
   Total glucose AUC (mg ⋅ min/mL)           7.38 ± 0.64     7.32 ± 0.37     7.22 ± 0.51                                    7.25 ± 0.63                                                                     7.22 ± 0.73   7.32 ± 0.63   7.14 ± 0.51                                  7.11 ± 0.74                                0.75     0.71
   Postprandial glucose AUC (mg ⋅ min/mL)    2.73 ± 0.27     2.68 ± 0.34     2.59 ± 0.13                                    2.68 ± 0.29                                                                     2.64 ± 0.40   2.57 ± 0.29   2.64 ± 0.15                                  2.53 ± 0.27                                0.79     0.63
   Total insulin AUC (IU ⋅ min/L)            170 ± 102       210 ± 83        198 ± 97                                       143 ± 49                                                                        212 ± 118     186 ± 123     171 ± 87                                     182 ± 128                                  0.08     0.44
   Postprandial insulin AUC (IU ⋅ min/L)     106 ± 64        133 ± 57        111 ± 52                                       77 ± 22                                                                         132 ± 85      114 ± 80      103 ± 55                                     109 ± 79                                   0.19     0.31
   Total free fatty acid AUC (mEq ⋅ min/L)   3.53 ± 0.70     3.76 ± 1.05     3.36 ± 0.31                                    3.37 ± 1.16                                                                     2.73 ± 0.86   3.20 ± 0.40   3.65 ± 1.09                                  3.76 ± 0.41                                0.36     0.68
   Fasting total cholesterol (mg/dL)         120 ± 24        132 ± 24        117 ± 16                                       136 ± 11                                                                        0.13                                                                                                                         
   Fasting LDL (mg/dL)                       71 ± 21         75 ± 21         62 ± 13                                        76 ± 10                                                                         0.20                                                                                                                         
   Fasting TG (mg/dL)                        57 ± 16         68 ± 27         68 ± 15                                        65 ± 22                                                                         0.31                                                                                                                         
   Fasting HDL (mg/dL)                       38 ± 7          44 ± 7          41 ± 7                                         46 ± 4[^d^](#t4n4){ref-type="table-fn"}                                         0.03                                                                                                                         
  Adipokine                                                                                                                                                                                                                                                                                                                              
   Leptin AUC (ng ⋅ min/mL)                  16 ± 5          15 ± 6          14 ± 3[^b^](#t4n2){ref-type="table-fn"}        12 ± 2[^a^](#t4n1){ref-type="table-fn"}^,^[^b^](#t4n2){ref-type="table-fn"}     29 ± 15       26 ± 11       25 ± 12                                      25 ± 11[^c^](#t4n3){ref-type="table-fn"}   0.01     0.002
   Adiponectin AUC (pg ⋅ min/mL)             99 ± 38         103 ± 37        117 ± 51[^b^](#t4n2){ref-type="table-fn"}      127 ± 49[^a^](#t4n1){ref-type="table-fn"}^,^[^b^](#t4n2){ref-type="table-fn"}   78 ± 31       77 ± 32       74 ± 32[^c^](#t4n3){ref-type="table-fn"}     82 ± 38[^c^](#t4n3){ref-type="table-fn"}   0.0007   0.0003
   FGF21 AUC (pg ⋅ min/mL)                   333 ± 57        411 ± 104       343 ± 46                                       460 ± 91[^a^](#t4n1){ref-type="table-fn"}^,^[^b^](#t4n2){ref-type="table-fn"}   350 ± 25      400 ± 80      370 ± 37                                     435 ± 75                                   0.28     0.10

Data are means ± SD. At the end of each testing month, subjects underwent acute thermometabolic evaluation at either 24°C or 19°C. ACTH, adrenocortotropic hormone.

^a^*P* \< 0.05 compared with 24°C during acute thermometabolic evaluation each month;

^b^*P* \< 0.05 (month 1 vs. 2),

^c^*P* \< 0.05 (months 2 vs. 4), and

^d^*P* \< 0.05 (months 1 vs. 4) compared with matching measurement at the same temperature performed at respective months as indicated.

BAT Changes {#s18}
-----------

[Figure 1*A*--*D*](#F1){ref-type="fig"} demonstrates BAT evolution in one representative subject throughout the 4-month sequential acclimation. [Supplementary Figs. 4--7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1) show individual results. [Figure 1*E--H*](#F1){ref-type="fig"} displays mean changes in BAT volume and overall fat metabolic activity, which increased upon cold acclimation (19°C) by 42 ± 18% (*P* \< 0.05) and 10 ± 11% (*P* \< 0.05), respectively; decreased after the thermoneutral month (24°C) to nearly baseline level; and completely muted at the end of the 1-month warm exposure period (27°C). BAT radiodensity, measured in HU, responded to acclimation with the same pattern (*P* \< 0.01) ([Table 1](#T1){ref-type="table"}). BAT HUs increased by 25 ± 8% after cold acclimation, reversed after the thermoneutral month, and by the end of warm acclimation in month 4, HU was 18 ± 11% lower than baseline values in month 1 ([Table 1](#T1){ref-type="table"}). In contrast, mean SUV of skeletal muscle and liver remained unchanged during acclimation ([Table 1](#T1){ref-type="table"}). Room (*P* \< 0.05) and individually exposed temperatures (*P* \< 0.01), but not outdoor temperatures, correlated with BAT changes during the study period ([Fig. 1*I* and *J*](#F1){ref-type="fig"} and [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)).

![Temperature-dependent BAT acclimation. *A*--*D*: Representative PET/CT fused images of the cervical-supraclavicular region (*left panels*: coronal view; *right panels*: transverse view) of one subject during monthly temperature acclimation. BAT (HU: −300 to −10 and SUV ≥2) is shown in red. Baseline BAT volume and mean SUV and activity were 26 mL and 2.65 and 0.238 MBq, respectively (*A*). All BAT parameters increased after 1 month of mild cold acclimation (19°C) (*B*), decreased to nearly baseline level after the thermoneutral month (24°C) (*C*), and BAT was nearly completely muted at the end of the 1-month mild warm exposure in the final month (27°C) (*D*). Mean fold changes (*N* = 5) of BAT volume (*E*) and mean SUV (*F*) and BAT activity (*G*), relative to month 1 (24°C), were significant across 4-month acclimation. Whole fat activity, as defined by ^18^F-fluodeoxyglucose uptake within tissue of fat density (HU: −300 to −10), followed the same pattern (*H*) and interacted significantly with temperature acclimation. Room (*I*) and individual exposed temperatures (*J*), but not environmental seasonal fluctuations (*I*), tracked BAT and whole fat metabolic changes in the predicted temperature-dependent manner. Correlative analysis between BAT parameters and temperature exposure is shown in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1). Individual PET/CT images and temperature profiles are shown in [Supplementary Figs. 4--7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1). \**P* \< 0.05 compared with month 1 (24°C); \#*P* \< 0.05 compared with month 2 (19°C).](3686fig1){#F1}

Cold- and Diet-Induced Thermogenesis {#s19}
------------------------------------

We next explored metabolic consequences of BAT acclimation. CIT response did not change significantly during temperature acclimation ([Table 2](#T2){ref-type="table"}). In contrast, DIT measured at 19°C rose by 32 ± 35% (*P* = 0.03) after cold acclimation. Progressive rewarming suppressed 19°C DIT response at months 3 and 4 to nearly baseline level. DIT measured at 24°C was unaltered ([Table 2](#T2){ref-type="table"}).

Shivering Response and Cold Sensitivity {#s20}
---------------------------------------

Surface EMG recordings of muscle fasciculation/shivering measured at 19°C and 24°C were not different ([Table 2](#T2){ref-type="table"}), indicating absence of significant shivering and validating our model in capturing nonshivering thermogenesis. Monthly acclimation did not alter EMG recordings, and subjects did not report changes in cold perception at 19°C during monthly calorimeter testing ([Supplementary Fig. 9](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)).

Diet and Body Composition {#s21}
-------------------------

Neither total caloric nor macronutrient content of intake changed during acclimation ([Table 3](#T3){ref-type="table"}). Biweekly hunger and satiety scores did not change significantly ([Table 3](#T3){ref-type="table"}); however, volunteers reported an increase in desire to eat and reduction in satiety during ad libitum meal test after cold acclimation, which reversed during the warm months ([Supplementary Fig. 10](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0513/-/DC1)). Body composition was unaltered across the study period ([Table 3](#T3){ref-type="table"}).

Pituitary-Thyroid-Adrenal Axis {#s22}
------------------------------

To elucidate potential endocrine mediators of BAT acclimation, we profiled pituitary-thyroid-adrenal axes ([Table 4](#T4){ref-type="table"}). Cold acclimation increased free triiodothyronine (T3) AUC measured at 24°C but not at 19°C. Free T3 to free thyroxine (T4) ratio (an indicator of peripheral T4 to T3 conversion \[[@B34]\]) was greater by 11 ± 5% (*P* = 0.01), measured at 24°C. No significant changes were observed in thyrotropin (thyroid-stimulating hormone \[TSH\]) or the pituitary-adrenal axis.

Insulin Sensitivity {#s23}
-------------------

Total glucose and insulin AUCs did not change during acclimation ([Table 4](#T4){ref-type="table"}). In contrast, postprandial insulin excursion measured at 19°C reached a nadir after cold acclimation, without significant changes to glucose excursion ([Fig. 2*A* and *B*](#F2){ref-type="fig"}). Indices of insulin sensitivity and resistance showed significant reciprocal changes during cold and warm acclimation, consistent with an improvement of postprandial whole-body insulin sensitivity after cold acclimation ([Fig. 2*C* and *D*](#F2){ref-type="fig"}). These changes were absent during measurements at 24°C ([Fig. 3*A*--*D*](#F3){ref-type="fig"}).

![Metabolic consequences of BAT acclimation at 19°C. *A* and *B*: Comparison of postprandial glucose and insulin excursions after a mixed meal at 1300 h before and after cold acclimation, respectively, measured at 19°C. Glucose excursions were unchanged but insulin levels decreased, with a significant reduction in AUC, after mild cold acclimation (month 2). Accordingly, adipocyte insulin resistance (IR) was the lowest (*C*) and Matsuda index (an indicator of insulin sensitivity) was the highest (*D*) after cold acclimation (month 2). These changes in glucose metabolism were accompanied by an increase in circulating adiponectin (*E*) and a decrease in circulating leptin (*F*). Cold acclimation--induced changes (months 1 and 2) in circulating adiponectin (*G*) and leptin levels (*H*) correlated negatively with changes in BAT activity. Adiponectin and leptin mRNA displayed concordant changes in subcutaneous adipose tissue biopsies with circulating levels, and changes in *GLUT4* tracked those of adiponectin (*I*). ^a^*P* \< 0.05 compared with month 1 (24°C), ^b^*P* \< 0.05 compared with month 2 (19°C), ^c^*P* \< 0.05 compared with month 3 (24°C), and ^d^*P* \< 0.05 compared with month 4 (27°C).](3686fig2){#F2}

![Metabolic consequences of BAT acclimatization at 24°C. *A* and *B*: Comparison of postprandial glucose and insulin excursions after a mixed meal at 1300 h before and after cold acclimatization, respectively, measured at 24°C. Unlike measurements at 19°C ([Fig. 2*A* and *B*](#F2){ref-type="fig"}), no significant changes were observed in glucose or insulin excursions. Accordingly, adipocyte insulin resistance (IR) (*C*) and Matsuda index (an indicator of insulin sensitivity) (*D*) were unchanged. Circulating adiponectin increased (*E*), while leptin decreased (*F*), identical to measurements observed at 19°C ([Fig. 2*E* and *F*](#F2){ref-type="fig"}). Cold acclimatization--induced changes (months 1 and 2) in circulating adiponectin (*G*) and leptin levels (*H*) correlated negatively with changes in BAT activity. In contrast to that observed in adipose tissue ([Fig. 2*I*](#F2){ref-type="fig"}), adiponectin and *GLUT4* mRNA did not change significantly in muscle (*I*). ^c^*P* \< 0.05 compared with month 3 (24°C); ^d^*P* \< 0.05 compared with month 4 (27°C).](3686fig3){#F3}

Adipokine Changes {#s24}
-----------------

Given our recent demonstration of BAT as an endocrine organ in humans ([@B19],[@B32],[@B35]), we probed adipokine changes during acclimation. Adiponectin AUC was augmented by 22 ± 9% (*P* \< 0.001) after cold acclimation ([Fig. 2*E*](#F2){ref-type="fig"}). Not only was enhancement of adiponectin levels observed at 19°C during acute thermometabolic evaluation, but similar increase also occurred at 24°C (*P* \< 0.001) ([Fig. 3*E*](#F3){ref-type="fig"}). In contrast, cold acclimation reduced leptin AUC by 14 ± 28% (*P* \< 0.001), evident at both 19°C ([Fig. 2*F*](#F2){ref-type="fig"}) and 24°C ([Fig. 3*F*](#F3){ref-type="fig"}). These dichotomized changes returned almost to baseline during the thermoneutral third month, trending to the opposite directions at the end of the fourth month at 27°C (*P* \< 0.05). Changes in circulating adiponectin and leptin correlated negatively with changes in BAT activity after cold acclimation ([Fig. 2*G* and *H*](#F2){ref-type="fig"} and [Fig. 3*G* and *H*](#F3){ref-type="fig"}). FGF21 AUC rose after cold acclimation, although overall trend did not reach significance ([Table 4](#T4){ref-type="table"}).

Fat and Muscle Gene Expression {#s25}
------------------------------

For exploration of sources of adipokine and origins of metabolic changes, fat and muscle biopsies were obtained from four volunteers at the end of each month. Adiponectin and *GLUT4* expression in adipose tissue ([Fig. 2*I*](#F2){ref-type="fig"}), but not muscle ([Fig. 3*I*](#F3){ref-type="fig"}), rose after cold acclimation, while expression of leptin fell, and their respective trends reversed after thermoneutral and warm acclimation months (*P* \< 0.05). Expression of *CIDEA*, a BAT gene governing lipid mobilization ([@B36]), increased after cold acclimation but decreased during rewarming ([Fig. 4](#F4){ref-type="fig"}). No other BAT/beige fat gene changes were observed.

![BAT and beige fat gene changes in adipose tissue biopsies across 4-month acclimatization. *A*: Changes in general BAT gene expression (general BAT genes are defined as genes ascribed to general BAT function and do not indicate their developmental origin). Expression of *CIDEA*, but not others, changed significantly (*P* = 0.04) during acclimatization across 4-month period. *B*: Changes in classic BAT gene expression. Classic BAT genes are defined as those expressed in interscapular BAT in animals or human infants ([@B50]). *C*: Changes in beige fat gene expression. Beige fat genes are defined as those expressed in inducible brown adipocytes, also known as brite or beige adipocytes, found within WAT depots. No significant changes were observed in classic BAT or beige fat genes across temperature acclimation.](3686fig4){#F4}

Discussion {#s26}
==========

The major finding of our study is the demonstration of BAT acclimation and its metabolic consequences by minimal manipulation of overnight temperature exposure while allowing usual daily activities. Human BAT is inducible and suppressible by controlled mild cold and warm exposure, respectively, independent of seasonal fluctuations. BAT acclimation is accompanied by boosting of DIT and postprandial insulin sensitivity. Mechanistically, this is associated with reciprocal changes of circulating adiponectin and leptin, mirrored by corresponding transcriptosomal changes in adipose tissue ex vivo*.* These results provide the first evidence linking ambient temperature, BAT acclimation, and whole-body energy/substrate metabolism in humans.

Consistent with previous reports ([@B25],[@B26]), we confirmed BAT recruitability by cold exposure but did not observe significant CIT response augmentation; the latter could be a type 2 error. Despite tentalizing associative data linking BAT abundance with favorable energy metabolism in humans, it remains unclear, to date, whether BAT recruitment is accompanied by metabolic benefits. We specifically sought to determine the significance of BAT recruitment and revealed an association of BAT acclimation with enhancement of postprandial energy metabolism and insulin sensitization. Within the allowance and feasibility of human research, we explored underlying mechanisms through blood and tissue analyses.

First, within the pituitary-thyroid-adrenal axis, we observed an increase in T3-to-T4 ratio, which indicates enhanced T3 synthesis. Given the enrichment of BAT with type 2 deiodinase ([@B37]) and our previous report showing severe insulin resistance amelioration by thyroid hormone-mediated BAT activation ([@B38]), we hypothesize heightened T3 synthesis within BAT to be one plausible mechanism underlying acclimated-BAT associated metabolic changes. Such a pattern of increased thyroid hormone turnover in the absence of TSH changes is reminiscent of cold adaptation observed among Arctic residents ([@B39]).

Second, our adipokine profiling uncovered an intriguing relation between BAT, adiponectin, and leptin. Cold acclimation augmented circulating adiponectin but decreased leptin. It is tempting to speculate that cold-induced adiponectin, a potent insulin sensitizer, contributes to glucose metabolism improvement and leptin reduction, with the latter as a result of improved tissue sensitivity. Concordant gene changes in adipose adiponectin and leptin, absent in muscle, argue adipose to be the primary effector. Surprisingly, circulating adiponectin related negatively with BAT activity, suggesting that PET-detectable BAT was not the source of cold-induced adiponectin. As BAT exhibits insulin-independent glucose uptake capacity ([@B40]), lesser BAT expansion could have triggered alternative glucose utilizing pathways in WAT during cold acclimation, evident by observed WAT *GLUT4* upregulation. Interestingly, such changes in circulating adiponectin and leptin were not limited to the cold-exposed condition ([Fig. 2](#F2){ref-type="fig"}) but persisted at thermoneutrality ([Fig. 3](#F3){ref-type="fig"}), indicating that the temperature-acclimated hormonal milieu was not totally dependent on BAT activation. The corollary is that acclimated BAT could be serving beneficial metabolic functions not related to temperature regulation per se.

Third, newly identified cytokines, such as FGF21, may mediate temperature-acclimated tissue cross-talk. Recent identification of a FGF21-adiponectin feed-forward axis ([@B41]) led us to wonder whether FGF21 augmentation after cold acclimation could have brought forth the adiponectin rise. When BAT was muted at the end of warm acclimation and adiponectin dwindled, FGF21 did not fall, suggesting that non-BAT FGF-secreting tissues might have compensated in states of relative BAT deficiency.

Fourth, although we did not observe an increase in beige fat gene expression, possibly due to the small sample size, we speculate fat browning to be a possibility. This is corroborated by finding an increased expression of the BAT gene *CIDEA* in adipose tissue after cold acclimation. Although ethics considerations prohibited serial neck fat biopsies in our volunteers, changes in radiodensity within BAT by PET/CT have offered insight on tissue changes. Adipose tissue is typically characterized by HU between −10 and −300, in contrast to muscle tissue, whose HU is within the positive range. Compared with WAT, BAT has relatively less lipid, as it is filled with abundant mitochondria and blood vessels. This is exemplified by water-fat separated magnetic resonance imaging revealing a lower fat fraction in activated BAT both in humans ([@B42]) and in rodents ([@B43]). We speculate that the rise and fall in BAT radiodensity with cold and warm acclimation, respectively, could be reflections of WAT → BAT transformation (or fat browning). This is also supported by previous studies demonstrating cell-autonomous ([@B44]) and endocrine-mediated ([@B19]) cold-induced WAT browning in humans. Further studies are required to ascertain whether WAT browning contributes to cold-acclimated BAT-induced metabolic changes.

Collectively, our results infer a complex concerted BAT-WAT response to cold acclimation, which could involve interplay between CIDEA-mediated lipid mobilization ([@B45],[@B46]), GLUT4-enhanced glucose utilization, and FGF21/adiponectin-induced insulin sensitization. Most importantly, all these changes occurred in the absence of measureable EE, caloric intake, or body compositional alterations, suggesting such responses to be primary cold-induced metabolic sequelae rather than compensatory physiologic adaptations. Nonetheless, because the desire to eat heightened after cold acclimation, we cannot exclude the possibility that appetite stimulation could diminish metabolic benefits of BAT recruitment if it increases caloric intake in longer-term studies.

The inducibility, suppressibility, and plasticity of human BAT entail implications beyond thermoregulatory physiology. The translation of recently discovered BAT activators in the laboratory to pharmacologic BAT stimulants available for clinical use is not a trivial process ([@B23]). Our study substantiates, in contrast, a simple BAT-modulating strategy: a mild reduction in environmental temperature is capable of recruiting BAT and yielding associated metabolic benefits; conversely, even a small elevation in ambient temperature could impair BAT and dampen previously attained metabolic benefits. Such reversible metabolic switching, occurring within a temperature range achievable in climate-controlled buildings, therefore carries therapeutic implications of BAT acclimation both on an individual and a public health level. Bedroom temperature has gradually increased from 19°C to 21.5°C over the last three decades in the U.S. ([@B47]). The blunting of BAT function due to widespread use of indoor climate control could be a neglected contribution to the obesity epidemic. Moderate downward adjustment of indoor temperature could represent a simple and plausible strategy in dampening the escalation of obesity on a population level. Our volunteers reported satisfactory sleep during acclimation, although more formal assessment of sleep quality is required in future studies.

Our findings should be viewed as a proof of concept illustrating human BAT plasticity. We acknowledge the small sample size to be a limitation of our study. Unfortunately, the conduct of long-term acclimation study necessitated substantial resources and regrettably prohibited a large sample size. Despite a small study population, the investigations were undertaken in a tightly monitored and controlled yet real-life simulating and applicable setting encompassing the most comprehensive spectrum of energy balance/metabolism to date to tackle a question fundamental to human BAT research: What is the significance of BAT recruitment? The unveiled positive relation between acclimated BAT and glucose homeostasis is clinically relevant. Glucose intolerance is an independent risk factor of cardiovascular mortality, and postprandial hyperglycemia is its earliest manifestation ([@B48]). We emphasize that a causal linkage could not be definitely ascertained between BAT recruitment and postprandial insulin sensitivity improvement; however, our study provides compelling circumstantial evidence supporting a potential therapeutic role of BAT in impaired glucose metabolism and calls for the investigation of similar temperature acclimation in individuals with impaired glycemia. Our observation of BAT recruitment accompanied by insulin sensitization in the absence of significant weight loss echoes animal findings showing glucose homeostasis improvement after fat browning to be greater than expected from adiposity reduction alone ([@B49],[@B50]). Whether it was indeed a result of fat phenotypic and/or adipokine changes merits further studies.

In summary, temperature acclimation modulates BAT abundance and activity, subsequently impacting energy and substrate metabolism in humans. BAT exhibits thermal plasticity intimately related to glucose homeostasis. Harnessing BAT by simple adjustment of ambient temperature could be a new strategy in the combat against obesity, diabetes, and related disorders.
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###### Supplementary Data

Clinical trial reg. no. NCT01730105, [clinicaltrials.gov](http://clinicaltrials.gov).
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